Abbott Laboratories has agreed to pay approximately $670 million to resolve a portion of the lawsuits alleging that its specialty infant formulas for premature babies were linked to necrotizing enterocolitis (NEC), a serious and potentially fatal bowel disease. The agreement covers claims involving about 2,000 individuals and includes a major case in which a jury previously awarded $495 million to an Illinois mother. Abbott has maintained that the settlement is not an admission of liability and continues to stand by the safety of its products.
The settlement represents one of the largest financial resolutions in the ongoing litigation surrounding preterm infant nutrition products. However, it does not end the broader legal battle. Abbott said approximately 1,700 lawsuits involving claims on behalf of around 12,700 infants remain pending after the agreements covered by the $670 million settlement.
Abbott Agrees To $670 Million Settlement
Abbott said it reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals. The total settlement amount is about $670 million.
The agreement covers litigation involving Abbott’s specialty formulas designed for premature infants and human milk fortifiers. These are specialized medical products used in hospital settings and are different from ordinary infant formula sold to consumers in retail stores.
| Abbott Settlement Details | Figure |
|---|---|
| Total settlement | ~$670 million |
| Claims covered | ~2,000 individuals |
| Law firms involved | 3 |
| Major prior verdict | $495 million |
| Original Gill verdict | July 2024 |
| Remaining lawsuits | ~1,700 |
| Infants represented in remaining claims | ~12,700 |
| Abbott admission of liability | No |
The settlement is a compromise of disputed claims. Abbott has explicitly said that it is not admitting liability as part of the agreements. :contentReference[oaicite:3]{index=3}
What The Settlement Resolves
The agreement includes the Gill case, which became one of the most closely watched lawsuits in the broader litigation.
In July 2024, a St. Louis jury awarded $495 million in damages to the plaintiff after finding that Abbott’s formula caused an Illinois girl’s NEC. Abbott appealed the decision, but the Missouri Court of Appeals upheld the verdict in May 2026. :contentReference[oaicite:4]{index=4}
Rather than continuing the appeal or potentially paying approximately $600 million, including the judgment and accrued interest, Abbott agreed to resolve the case as part of the broader $670 million settlement. :contentReference[oaicite:5]{index=5}
What Is Necrotizing Enterocolitis?
Necrotizing enterocolitis, commonly called NEC, is a serious intestinal disease that primarily affects premature newborns. The condition can cause intestinal tissue to become inflamed and die and can require intensive medical treatment.
The disease has a high mortality rate, with Reuters reporting an estimated mortality rate of more than 20%. :contentReference[oaicite:6]{index=6}
| NEC Characteristic | Details |
|---|---|
| Full name | Necrotizing enterocolitis |
| Common abbreviation | NEC |
| Primarily affects | Premature infants |
| Main organ affected | Intestines |
| Potential complication | Intestinal tissue death |
| Severity | Potentially life-threatening |
| Reported mortality rate | More than 20% |
The lawsuits allege that Abbott’s specialty formulas increased the risk of NEC and that the company failed to adequately warn about those risks.
Abbott disputes those allegations.
Abbott Maintains Its Products Are Safe
Despite agreeing to the settlement, Abbott continues to deny that its products cause NEC.
The company said it remains confident in the safety of its specialty formulas and the science supporting their use in premature infants. Abbott also pointed to support from medical and regulatory organizations, saying there is no reliable scientific evidence that its products cause NEC. :contentReference[oaicite:7]{index=7}
This distinction is important when interpreting the $670 million agreement.
A settlement does not necessarily mean that the allegations have been proven. In this case, Abbott specifically characterized the agreements as a compromise of disputed claims and not an admission of liability.
| Issue | Abbott’s Position |
|---|---|
| Product safety | Abbott stands by its products |
| NEC allegations | Abbott disputes that its products cause NEC |
| $670M settlement | Compromise of disputed claims |
| Admission of liability | None |
| Further litigation | Continues |
| Medical necessity | Abbott says products remain important for preterm infants |
The $495 Million Gill Verdict Was A Major Turning Point
The Gill case has played a significant role in the legal battle.
The original jury award of $495 million represented a substantial financial liability for Abbott. After the Missouri Court of Appeals affirmed the verdict in May 2026, Abbott faced the prospect of continuing its appeal or resolving the case.
Abbott said that continuing to appeal or paying the judgment with accrued interest could have resulted in a payment of approximately $600 million for the Gill case alone. :contentReference[oaicite:8]{index=8}
The settlement therefore combines the resolution of the Gill case with approximately 2,000 additional claims.
| Gill Case Timeline | Development |
|---|---|
| July 2024 | Jury awards $495 million |
| December 2024 | Abbott appeals |
| May 2026 | Missouri appeals court upholds verdict |
| August 2026 | Abbott agrees to broader settlement |
| Settlement amount | ~$670 million |
The broader agreement allows Abbott to resolve a significant group of claims while avoiding continued litigation costs and uncertainty associated with the appeal.
Thousands Of Other Claims Remain
The $670 million agreement does not represent a global settlement of all NEC-related litigation involving Abbott.
After the settlement, approximately 1,700 lawsuits involving claims on behalf of roughly 12,700 infants remain, according to Abbott. :contentReference[oaicite:9]{index=9}
This means the company still faces significant legal exposure.
| Litigation Position After Settlement | Approximate Figure |
|---|---|
| Claims covered by new settlement | ~2,000 |
| Lawsuits remaining | ~1,700 |
| Infants represented by remaining claims | ~12,700 |
| Total settlement | ~$670 million |
The remaining cases are being pursued in both federal and state courts.
More than 800 cases had been consolidated in an Illinois federal court, with other cases pending in states including Illinois, Missouri and Pennsylvania. :contentReference[oaicite:10]{index=10}
Federal And State Cases Have Produced Mixed Results
The litigation has not produced a uniform outcome for Abbott.
Abbott said it prevailed in all three federal Multidistrict Litigation bellwether cases involving its preterm formulas. The company also highlighted favorable rulings in several state and federal proceedings. :contentReference[oaicite:11]{index=11}
At the same time, the company has faced significant adverse verdicts in state courts, most notably the $495 million Gill award.
Abbott’s latest regulatory filing also acknowledged that outcomes in state court cases have varied, ranging from summary judgments in the company’s favor to the $495 million plaintiff verdict. :contentReference[oaicite:12]{index=12}
| Litigation Outcome | Abbott’s Reported Experience |
|---|---|
| Federal MDL bellwether cases | Abbott prevailed in all three |
| Gill state case | $495M plaintiff verdict |
| Illinois state litigation | Mixed outcomes |
| Missouri litigation | Appeals pursued |
| Federal litigation | Continuing |
| Overall litigation | Unresolved |
The mixed results make the remaining lawsuits difficult to predict.
Scientific Debate Remains Central To The Cases
At the heart of the litigation is a disagreement over the relationship between specialized formula and NEC.
Plaintiffs argue that Abbott’s products can increase the risk of the disease and that parents and medical professionals were not adequately warned.
Abbott and other formula manufacturers have argued that breast milk has protective benefits and that their products themselves do not cause NEC. :contentReference[oaicite:13]{index=13}
Reuters also reported that U.S. regulatory agencies and an NIH-convened working group in 2024 concluded that available evidence linked higher NEC rates to the absence of breast milk rather than to formula use. :contentReference[oaicite:14]{index=14}
This scientific disagreement is likely to remain important in the remaining litigation.
The Products Involved Are Specialized Medical Formulas
Another important detail is the type of products involved.
The lawsuits concern specialty formulas for premature infants and products used to fortify human milk. These are primarily used in hospital settings and are not ordinary infant formulas sold through supermarkets and other retail channels. :contentReference[oaicite:15]{index=15}
| Product Category | Litigation Relevance |
|---|---|
| Specialized preterm formula | Yes |
| Human milk fortifier containing cow’s milk ingredients | Yes |
| Hospital-use nutrition products | Yes |
| Ordinary retail infant formula | Not the products at issue |
| General consumer baby food | Not the focus |
This distinction matters because consumers could otherwise mistakenly assume that the settlement concerns all Abbott infant-formula products.
Abbott’s Financial Exposure Remains Uncertain
Abbott’s latest SEC filing shows that the company had not previously recorded reserves for the NEC litigation because management said it could not reasonably estimate the range of potential losses given the uncertainty surrounding individual cases. :contentReference[oaicite:16]{index=16}
The filing also stated that Abbott believed the ultimate resolution of its various legal proceedings would not have a material adverse effect on its financial position, cash flows or results of operations, although individual cases could have different outcomes. :contentReference[oaicite:17]{index=17}
The new $670 million agreement changes the immediate financial picture for the claims covered by the settlement, but it does not establish the eventual cost of the remaining litigation.
| Financial Issue | Current Status |
|---|---|
| New settlement | ~$670 million |
| Gill verdict | Included in settlement |
| Remaining claims | Substantial |
| Total future liability | Uncertain |
| Previous NEC reserves | None recorded due to uncertainty |
| Abbott’s position | No material adverse effect expected overall |
Mead Johnson Is Also Facing NEC Litigation
Abbott is not the only manufacturer facing lawsuits related to NEC and preterm infant formula.
Mead Johnson, a unit of Reckitt, manufactures Enfamil products and has also been named in similar lawsuits. The broader litigation has involved claims against both companies. :contentReference[oaicite:18]{index=18}
The cases involving the two manufacturers are proceeding through both federal and state courts, with outcomes differing from one case to another.
This makes the litigation important for the wider specialized infant-nutrition industry rather than Abbott alone.
The Settlement Could Reduce Some Legal Uncertainty
From Abbott’s perspective, resolving approximately 2,000 claims provides a degree of certainty.
Large-scale litigation can create years of legal expenses, management attention and uncertainty over potential damages. Settling a significant group of cases allows the company to remove those claims from the active litigation pipeline.
However, the remaining 1,700 lawsuits mean the overall legal risk has not disappeared.
Why Abbott Chose Settlement
Several factors could have influenced the decision:
| Factor | Potential Significance |
|---|---|
| $495M Gill verdict | Established major litigation risk |
| Appeal upheld | Reduced certainty of overturning verdict |
| Accrued interest | Increased potential Gill payment |
| ~2,000 claims | Large group of related cases |
| Ongoing litigation costs | Continued financial burden |
| Remaining lawsuits | Risk remains despite settlement |
Abbott itself said the agreements were in the company’s long-term best interest and represented a constructive step toward substantially resolving the overall litigation. :contentReference[oaicite:19]{index=19}
What The Settlement Means For Abbott
The $670 million agreement represents a significant financial commitment, but its strategic importance extends beyond the dollar value.
The settlement removes the Gill case and approximately 2,000 additional claims from the litigation process. It also eliminates the immediate uncertainty surrounding the company’s appeal of the $495 million verdict.
At the same time, investors will continue to monitor the remaining lawsuits and any additional verdicts or settlements.
The company’s future exposure will depend heavily on how courts handle the scientific evidence, warning requirements and legal defenses in the remaining cases.
The Bigger Picture
Abbott’s $670 million settlement marks a major development in the long-running litigation over specialized formulas for premature infants. The agreement resolves the Gill case, which involved a $495 million jury verdict, along with claims involving approximately 2,000 other individuals. Abbott has not admitted liability and continues to maintain that its products are safe and that there is no reliable scientific evidence establishing that they cause NEC. :contentReference[oaicite:20]{index=20}
However, the agreement does not end the legal controversy. Approximately 1,700 lawsuits involving claims on behalf of about 12,700 infants remain pending, while federal and state courts have produced mixed outcomes in cases involving Abbott and competing manufacturer Mead Johnson. The scientific and legal questions surrounding NEC, breast milk and specialized formula are therefore likely to remain central to the litigation. :contentReference[oaicite:21]{index=21}
Looking Ahead
The immediate focus will shift toward the remaining lawsuits and whether additional cases are resolved through trials or negotiated settlements. Abbott’s decision to settle a major group of claims could reduce some uncertainty, but the large number of remaining cases means the company’s legal exposure is still significant. Future verdicts could also influence the terms of any additional settlements and shape how courts evaluate the scientific and warning-related arguments.
For the infant-nutrition industry, the litigation highlights the legal and scientific complexity surrounding specialized products used for premature babies. Abbott’s $670 million agreement provides a major resolution for thousands of claims but stops short of ending the broader dispute. The remaining cases will determine whether the settlement becomes a foundation for further resolutions or simply one stage in a much longer legal battle.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
